Skip to main content
. 2022 Jan 24;8:33. doi: 10.1038/s41420-022-00823-x

Fig. 1. miR-181a–2–3p inhibits apoptosis and OS of SH-SY5Y cells.

Fig. 1

A The box plot of miR-181a–2–3p in GSE16658, the blue box on the left indicated expression of normal samples, and the red box on the right indicates miR-181a–2–3p expression in PD patients. B Radioactive dopamine-uptake test. C Cell viability in SH-SY5Y cells treated with 6-OHDA determined with MTT assay. D Intracellular oxidation level evaluated after treatment with different drug concentrations. E LDH-release assay. F miR-181a-2-3p expression detected in SH-SY5Y cells treated with 6-OHDA for 24 h. G miR-181a–2–3p expression detected in 6-OHDA-induced SH-SY5Y cells using RT-qPCR. H SH-SY5Y cell proliferation detected using CCK-8 assay after 6-OHDA treatment. I Apoptosis of SH-SY5Y cells treated with 6-OHDA detected using flow cytometry. J SOD level in SH-SY5Y cells treated with 6-OHDA detected using SOD kit. K MDA level in SH-SY5Y cells treated with 6-OHDA detected using MDA kit. L ROS levels in SH-SY5Y cells treated with 6-OHDA detected using DCFH-DA fluorescent staining. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control or SH-SY5Y cells without treatment. Cell experiments were repeated three times independently.